A new pilot study asks whether adding an immune drug to targeted radiation helps patients with an aggressive form of neuroendocrine cancer. The honest answer, which the authors themselves give in their conclusion, is that the study cannot tell. It was not built to.
The trial, published in Clinical Cancer Research ↗, treated 26 patients with high-risk, well-differentiated neuroendocrine tumors. These are cancers that arise from hormone-producing cells and, in this group, were growing fast enough to be dangerous. Twenty of the 26 had grade 3 disease, the most aggressive category still classed as well-differentiated. Every patient received two treatments at once. The first was peptide receptor radionuclide therapy, or PRRT, a peptide that seeks out the somatostatin receptor ↗ on tumor cells and delivers a radioactive payload directly to them. The second was pembrolizumab, a checkpoint inhibitor, which is an antibody that releases a brake on the immune system so it can attack cancer.
The idea behind the combination is reasonable. Radiation kills tumor cells in a way that can spill their contents and alert the immune system, and checkpoint drugs work poorly against neuroendocrine tumors on their own. Pairing them might, in theory, turn a modest immune response into a useful one. The trial was designed to test whether that theory holds.
Here is the result. The objective response rate, meaning the share of patients whose tumors shrank by a preset amount on scans, was 35 percent. Median progression-free survival, the time until the cancer started growing again, was 13.3 months, ranging across patients from 2.1 to 33.4 months. Median overall survival was 24.1 months, ranging from 4.4 to 52.3 months. On their face these look like respectable numbers for an aggressive cancer.
The problem is that there is nothing to compare them to. This was a single-arm study, which means every patient got the same combination and no one received PRRT alone. So when 35 percent of tumors shrank, there is no way to know how many would have shrunk on the radiation treatment by itself. PRRT alone already produces response rates in roughly this neighborhood in similar patients. The combination might be adding real benefit, or it might be adding nothing at all, and this design cannot separate the two. A number without a comparison group is a number without a meaning.
Meanwhile, the cost side of the ledger is clearer. Severe adverse events occurred in 14 of the 26 patients, or 54 percent. The authors state plainly that this rate was higher than expected for PRRT alone, which points the finger at the added immune drug. The most common immune-related problems were mild liver inflammation in seven patients, an underactive thyroid in five, and new diabetes in four. These are the familiar signatures of checkpoint inhibitors, which can turn the immune system against healthy organs. So the combination looks more toxic than radiation by itself, while its extra benefit remains unproven.
There is one genuinely interesting thread. Patients who responded tended to have more actively dividing CD8 T cells, the immune system's tumor-killing cells, and fewer of a suppressive cell type called a myeloid-derived suppressor cell in their blood before treatment. That hints at a way to predict who might benefit. But in a single-arm study of 26 people, a biomarker like this is a lead to chase, not a finding to act on. It could easily reflect which patients had healthier immune systems to begin with.
The authors deserve credit for stating the limitation rather than burying it. Their conclusion is that the added benefit of the checkpoint drug remains unclear and that the toxicity was higher than radiation alone would produce. That is the correct reading. The next step is a randomized trial that gives some patients the radiation alone and others the combination, so the two can be compared directly. Until that exists, this pilot tells us the combination is feasible and more toxic. It does not tell us it works.